Follow us: facebook twitter linkedin
Login My ASCCP Search
CAP Pathology and Laboratory Quality Center and the ASCCP Consensus Conference:

The Lower Anogenital Squamous Terminology Standardization Project (The LAST Project)

The Lower Anogenital Squamous Terminology Standardization (The LAST Project) Consensus Conference was held March 13-14, 2012 at the Hyatt Regency San Francisco, in San Francisco, California. The Consensus Conference was co-sponsored by the College of American Pathologists Pathology and Laboratory Quality Center and the ASCCP and representatives from 35 medical organizations and federal agencies were in attedance to hear, debate, and vote upon key recommendations.

The primary goals of the conference were:
  • Standardize terminology used for reporting histopathology diagnoses of HPV-related mucocutaneous squamous lesions of the lower genital tract, including intraepithelial lesions and minimally invasive cancers but excluding non-HPV related dermatologic and vulvar lesions.
  • Harmonize terminology across the various lower anogenital tract sites with current evidence-based knowledge regarding the biology of HPV-related squamous lesions and their clinical management.
  • Harmonize the terminology for histopathology with the Bethesda System for reporting gynecologic and anal cytology (if applicable).
  • Assess the use of new technologies to validate proposed terminology standards, and provide guidelines for appropriate use.

Beginning on June 28, 2012, the final approved recommendations will be released by online joint publication in the Archives of Pathology & Laboratory Medicine and the Journal of Lower Genital Tract Disease. Print publication will follow in both journals.

Detailed information regarding the Project's 2011-12 comprehensive literature process, the COI policy, a list of the participating organizations, etc., may be found in the published Supplemental Digital Content.

LAST Consensus Recommendations and Resources

Copyright © 2016. All rights reserved.   Use of this Web site constitutes acceptance of our Terms of Use.